These findings are consistent with genetic data from neuroblastoma patients: only MYCN-amplified neuroblastoma tumors have significantly higher levels of DHODH mRNA expression compared with low-risk and high-risk neuroblastoma tumors without MYCN amplification. Here, MYCN is linked to neuroblastoma.